Supporting academic institutes and SMEs to identify and develop their commercial opportunities, from entrepreneurship coaching to investor pitching and beyond.

Development of the business case for an AI driven fragment-based drug discovery (AI-FBDD) firm and recruitment of strategic investors with $2 million raised in 2019. Structured an EU based subsidiary to leverage projects from research institutes and biopharma companies. Company was acquired by a large AI focused therapeutics developer in 2021.

Supported TissueGUARD GmbH in moving its innovative hydrogel products into the clinic and in closing a funding round. The company is developing breakthrough chemistry in degradable hydrogels and is currently partnered with world-leading clinicians in ophthalmology.

Creation of a business case for a computational drug discovery engine; validation of the technology and license negotiations with industry; partnering with big Pharma and with venture investors.

Evaluation of IP, business proposals and collaborative opportunities, with hands-on support for patent filing, start-up and licensing, and partnering with industry.

Established all aspects of operations in Saxony and managed three transfer projects in stem cell science and photonics.

Established JADO as a spin-out of the Max-Planck Institute of Molecular Cell Biology in Dresden to develop novel anti-inflammatory and anti-viral pharmaceuticals, targeting cell membrane rafts. JADO developed potent amphiphilic drug candidates for arthritis, urticaria, and mastocytosis.I served as CEO/CSO, raising 14 million Euro in Venture Capital from EU and US investors and led partnerships with EU and Japanese pharma companies.